0
Clinicopathologic Reports, Case Reports, and Small Case Series |

Verteporfin Photodynamic Therapy of Choroidal Neovascularization Secondary to Ocular Toxoplasmosis FREE

Robert Wirthlin, MD; Alice Song, MD; Julia Song, MD; Philip J. Rosenfeld, MD, PhD
[+] Author Affiliations

Section Editor: W. Richard Green,, MD

More Author Information
Arch Ophthalmol. 2006;124(5):741-743. doi:10.1001/archopht.124.5.741.
Text Size: A A A
Published online

Choroidal neovascularization (CNV) can arise secondary to the retinochoroiditis and macular scarring from ocular toxoplasmosis.1,2 Treatment of CNV due to toxoplasmosis can include corticosteroids, cryotherapy, laser photocoagulation, submacular surgery, and verteporfin photodynamic therapy (PDT).14 We describe 2 cases of CNV secondary to toxoplasmosis treated successfully with PDT.

Case 1. A 20-year-old man with a diagnosis of congenital ocular toxoplasmosis with bilateral macular scars sought care because of a 9-month history of decreasing vision and metamorphopsia in the right eye. Visual acuity was 1/200 OD. Fundus examination results revealed a subfoveal chorioretinal scar with surrounding subretinal hemorrhage and exudate (Figure 1A). Fluorescein angiographic images identified central leakage from the CNV with surrounding blocked fluorescence corresponding to the hemorrhage (Figure 1B and C), while indocyanine green angiographic images were able to provide visualization through the hemorrhage. The eye was treated with PDT and the greatest linear dimension of the treatment spot included all of the hemorrhage.

Place holder to copy figure label and caption
Figure 1

A, Baseline fundus photographs (OD, OS) show a macular scar with adjacent subretinal fluid, hemorrhage, and exudates in the right eye and a macular scar in the left eye. B and C, Baseline early- and late-phase fluorescein angiographic images showing leakage from choroidal neovascularization and hypofluorescence corresponding to hemorrhage. D, Posttreatment fundus photographs taken at 10 months showing a macular scar with no evidence of subretinal fluid, hemorrhage, or exudates. E and F, Posttreatment early- and late-phase fluorescein angiographic images taken at 10 months showing no evidence of leakage.

Graphic Jump Location

One week posttreatment, visual acuity improved to 20/200 OD. Six weeks posttreatment, a flat scar was present in the central macula with resolution of the hemorrhage and exudates. Six months posttreatment, visual acuity improved to 20/60 OD and has remained stable for more than 2 years (Figure 1D-F).

Case 2. A 15-year-old boy with a diagnosis of bilateral macular scars secondary to congenital ocular toxoplasmosis reported decreasing vision in his left eye. On examination, visual acuity was 20/100 OS. Fundus examination results revealed a macular scar with adjacent fibrosis, subretinal fluid, and hemorrhage (Figure 2A). Fluorescein angiographic images identified leakage from the CNV and blocked fluorescence corresponding to the hemorrhage (Figure 2B and C). Optical coherence tomographic images revealed increased retinal thickening and a highly reflective layer under the retina consistent with CNV (Figure 2D). The patient underwent PDT.

Place holder to copy figure label and caption
Figure 2

A, Baseline fundus photographs (OD, OS) show a macular scar with adjacent fibrosis, subretinal fluid, and the rim of hemorrhage in the left eye and a macular scar in the right eye. B and C, Baseline early- and late-phase fluorescein angiographic images show leakage from choroidal neovascularization and the rim of hypofluorescence corresponding to hemorrhage. D, Baseline vertical optical coherence tomographic scan shows increased retinal thickening and a highly reflective subretinal complex. E, Posttreatment fundus photographs taken at 6 months show a macular scar and no evidence of subretinal fluid or hemorrhage. F and G, Posttreatment early- and late-phase fluorescein angiographic images taken at 6 months show no evidence of leakage. H, Posttreatment vertical optical coherence tomographic scan taken at 6 months shows diminished retinal thickness and a persistent highly reflective subretinal complex.

Graphic Jump Location

One month following treatment, visual acuity improved to 20/80 OS. Fundus examination results showed a flat chorioretinal scar and complete resolution of subretinal fluid and blood. The patient's visual acuity and clinical appearance remained stable through 18 months of follow-up (Figure 2E-H).

Compared with other treatments, PDT has the theoretical advantage of selectively occluding the CNV, even in the presence of small amounts of overlying blood, without causing significant damage to the unaffected retina and choroid. Thus, PDT has the potential for vision improvement, especially in younger patients as shown in our cases. Furthermore, only a single treatment was necessary in both of these cases, unlike the 3 to 4 treatments routinely needed during the first year in patients with neovascular age-related macular degeneration.4 The decreased need for retreatment with PDT in these toxoplasmosis cases is similar to the retreatment rate observed in younger patients with postinflammatory CNV. While improvement could have occurred without PDT, these lesions were not in the process of resolving as suggested by the duration and progression of vision loss and the presence of new hemorrhages. Photodynamic therapy was most likely responsible for the observed improvements owing to the temporal relationship between treatment and the resolution of the CNV. To our knowledge, this is the second report of CNV secondary to toxoplasmosis treated with PDT5; the first report demonstrating a sustained visual acuity benefit from a single treatment with PDT, and the first successful use of PDT to treat a predominantly hemorrhagic lesion.

Correspondence: Dr Rosenfeld, Bascom Palmer Eye Institute, 900 NW 17th St, Miami, FL 33101 (prosenfeld@med.miami.edu).

Financial Disclosure: None.

Funding/Support: This study was supported by an unrestricted grant from Research to Prevent Blindness Inc, New York, NY, and grant P30 EY14801 from the National Institutes of Health, Bethesda, Md.

Willerson  DAaaberg  TM  SrReeser  FMeredith  TA Unusual ocular presentation of acute toxoplasmosis. Br J Ophthalmol 1977;61693- 698
PubMed
Fine  SLOwens  SLHaller  JAKnox  DLPatz  A Choroidal neovascularization as a late complication of ocular toxoplasmosis. Am J Ophthalmol 1981;91318- 322
PubMed
Adan  AMateo  CWolley-Dod  C Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis. Am J Ophthalmol 2003;135386- 387
PubMed
Rosenfeld  PJSaperstein  DABressler  NM  et al.  Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled open-label 2-year study. Ophthalmology 2004;1111725- 1733
PubMed
Oliveira  LBReis  PA Photodynamic therapy-treated choroidal neovascular membrane secondary to toxoplasmic retinochoroiditis. Graefes Arch Clin Exp Ophthalmol 2004;2421028- 1030
PubMed

Figures

Place holder to copy figure label and caption
Figure 1

A, Baseline fundus photographs (OD, OS) show a macular scar with adjacent subretinal fluid, hemorrhage, and exudates in the right eye and a macular scar in the left eye. B and C, Baseline early- and late-phase fluorescein angiographic images showing leakage from choroidal neovascularization and hypofluorescence corresponding to hemorrhage. D, Posttreatment fundus photographs taken at 10 months showing a macular scar with no evidence of subretinal fluid, hemorrhage, or exudates. E and F, Posttreatment early- and late-phase fluorescein angiographic images taken at 10 months showing no evidence of leakage.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2

A, Baseline fundus photographs (OD, OS) show a macular scar with adjacent fibrosis, subretinal fluid, and the rim of hemorrhage in the left eye and a macular scar in the right eye. B and C, Baseline early- and late-phase fluorescein angiographic images show leakage from choroidal neovascularization and the rim of hypofluorescence corresponding to hemorrhage. D, Baseline vertical optical coherence tomographic scan shows increased retinal thickening and a highly reflective subretinal complex. E, Posttreatment fundus photographs taken at 6 months show a macular scar and no evidence of subretinal fluid or hemorrhage. F and G, Posttreatment early- and late-phase fluorescein angiographic images taken at 6 months show no evidence of leakage. H, Posttreatment vertical optical coherence tomographic scan taken at 6 months shows diminished retinal thickness and a persistent highly reflective subretinal complex.

Graphic Jump Location

Tables

References

Willerson  DAaaberg  TM  SrReeser  FMeredith  TA Unusual ocular presentation of acute toxoplasmosis. Br J Ophthalmol 1977;61693- 698
PubMed
Fine  SLOwens  SLHaller  JAKnox  DLPatz  A Choroidal neovascularization as a late complication of ocular toxoplasmosis. Am J Ophthalmol 1981;91318- 322
PubMed
Adan  AMateo  CWolley-Dod  C Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis. Am J Ophthalmol 2003;135386- 387
PubMed
Rosenfeld  PJSaperstein  DABressler  NM  et al.  Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled open-label 2-year study. Ophthalmology 2004;1111725- 1733
PubMed
Oliveira  LBReis  PA Photodynamic therapy-treated choroidal neovascular membrane secondary to toxoplasmic retinochoroiditis. Graefes Arch Clin Exp Ophthalmol 2004;2421028- 1030
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles